What should be the primary target of "treat to target" in psoriatic arthritis?
<h4>Background</h4> <p>Treat to Target in psoriatic arthritis (PsA) recommendations have stated that the target should be remission or inactive disease. Potential definitions include Very Low Disease Activity (VLDA), PsA Disease Activity Score (PASDAS) near remission, Disease Act...
Main Authors: | Coates, LC, Lubrano, E, Perrotta, FM, Emery, P, Conaghan, PG, Helliwell, PS |
---|---|
Formato: | Journal article |
Idioma: | English |
Publicado: |
Journal of Rheumatology
2018
|
Títulos similares
-
What should be the primary target of ‘treat to target’ in PsA?
por: Coates, L, et al.
Publicado: (2018) -
Treat-to-target in psoriatic arthritis—cost-effective in the biosimilar era
por: Coates, L, et al.
Publicado: (2022) -
Long-term follow-up of patients in the TIght COntrol of inflammation in early Psoriatic Arthritis (TICOPA) trial
por: Coates, L, et al.
Publicado: (2019) -
Sustained very low disease activity and remission in psoriatic arthritis patients
por: Lubrano, E, et al.
Publicado: (2019) -
New approved drugs for psoriatic arthritis
por: F.M. Perrotta, et al.
Publicado: (2016-09-01)